
EHR-enabled access has the potential to streamline ordering, accelerate clinical decisions, and drive scalable precision oncology adoption


NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic

<p xmlns="http://www.w3.org/1999/xhtml" class="bwalignc">
<i xmlns="http://www.w3.org/1999/xhtml">EHR-enabled access has the potential to streamline ordering, accelerate clinical decisions, and drive scalable precision oncology adoption</i>

</p><p xmlns="http://www.w3.org/1999/xhtml">
<a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.neogenomics.com%2F&amp;esheet=54521005&amp;newsitemid=20260423070414&amp;lan=en-US&amp;anchor=NeoGenomics%2C+Inc.&amp;index=1&amp;md5=624fc482590560018e674c4510e90ddf" shape="rect">NeoGenomics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/NEO">NEO</a>), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that its oncology testing portfolio is now available through <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fshowroom.epic.com%2Fstage%3Fid%3D36&amp;esheet=54521005&amp;newsitemid=20260423070414&amp;lan=en-US&amp;anchor=Epic+Aura&amp;index=2&amp;md5=a48ffc8c690ddc2cf9de757655d23838" shape="rect">Epic Aura</a>, enabling seamless access to oncologists and health systems across the United States through the Epic electronic health record (EHR) workflow.

</p><p xmlns="http://www.w3.org/1999/xhtml">
Through this integration, physicians can order NeoGenomics' comprehensive suite of tests, spanning solid tumors and hematologic malignancies, and view results in the same system they use to manage patient care. This streamlined approach lowers barriers to entry for hospitals and health systems, enhances the scalability of NeoGenomics' testing capabilities, and could drive 20-30% increase<sup xmlns="http://www.w3.org/1999/xhtml">1</sup> in test adoption per site, supporting faster time to treatment for patients facing a cancer diagnosis.

</p><p xmlns="http://www.w3.org/1999/xhtml">
"Clinicians need timely access to the right diagnostics within the systems they already rely on," said Tony Zook, Chief Executive Officer of NeoGenomics. "Successfully integrating with Epic enables us to bring our testing capabilities directly into everyday care delivery, with the potential to help patients begin appropriate therapy sooner while allowing health systems to scale precision oncology more efficiently."

</p><p xmlns="http://www.w3.org/1999/xhtml">
This integration represents a significant step forward in NeoGenomics' digital health strategy, strengthening connectivity across community oncology practices and large health systems. This scalable, "build once, deploy broadly" infrastructure will support the delivery of next-generation diagnostic capabilities, including liquid biopsy and molecular residual disease (MRD).

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">About NeoGenomics</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Forward Looking Statements</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "plan," "can," "could," "would," "may," "will," "believe," "estimate," "forecast," "goal," "project," "guidance," "potential," "intend," "seek," "target" and other words of similar meaning, although not all forward-looking statements include these words. These forward-looking statements include, but are not limited to, statements regarding the expected benefits of the Epic Aura integration, including the potential to streamline test ordering, accelerate clinical decisions, drive adoption of precision oncology, increase test adoption per site and support faster time to treatment, as well as the Company&#39;s Digital Health strategy and the anticipated delivery of next-generation diagnostic capabilities. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Applicable risks and uncertainties include, among others, risks related to the Company's ability to successfully implement and maintain the Epic Aura integration, the willingness of health systems and physicians to adopt the integrated ordering workflow, the Company's ability to achieve projected increases in test adoption, the timing and success of the Company's Digital Health strategy, general market conditions, competitive dynamics and the risks identified under the heading &#34;Risk Factors&#34; contained in the Company&#39;s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the Company&#39;s other filings with the Securities and Exchange Commission.

</p><p xmlns="http://www.w3.org/1999/xhtml">
We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=54521005&amp;newsitemid=20260423070414&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=3&amp;md5=4057d3cf27d552d824b8984c63a9c533" shape="rect">www.sec.gov</a> and in the "Investors" section of our website at ir.neogenomics.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements, whether as a result of new information, future events or otherwise, except as required by law. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Reference</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
1. Huelsman K, Vasiliadis L, Liette A, Wernke K, Parchman A, Maher J, Rice C. Integrating discrete genomic data with an EHR improves patient care, provider satisfaction, and program metrics. <i xmlns="http://www.w3.org/1999/xhtml">Association of Cancer Care Centers</i>. 2024;39(2):12-24. Accessed April 21, 2026. <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fcdn.sanity.io%2Ffiles%2F0vv8moc6%2Faccc-cancer%2Fb351ee63a2f4679660f6e409dd3564c61d15e212.pdf&amp;esheet=54521005&amp;newsitemid=20260423070414&amp;lan=en-US&amp;anchor=https%3A%2F%2Fcdn.sanity.io%2Ffiles%2F0vv8moc6%2Faccc-cancer%2Fb351ee63a2f4679660f6e409dd3564c61d15e212.pdf&amp;index=4&amp;md5=257df8c8c12ed14cf6de7dffd82122c0" shape="rect">https://cdn.sanity.io/files/0vv8moc6/accc-cancer/b351ee63a2f4679660f6e409dd3564c61d15e212.pdf</a>

</p><p xmlns="http://www.w3.org/1999/xhtml"><img xmlns="http://www.w3.org/1999/xhtml" alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260423070414r1&amp;sid=benz2&amp;distro=nx&amp;lang=en" style="width:0;height:0"></img><span xmlns="http://www.w3.org/1999/xhtml" class="bwct31415"></span></p><p xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink"><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-phrase">View source version on businesswire.com: </span><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-link"><a xmlns="http://www.w3.org/1999/xhtml" href="https://www.businesswire.com/news/home/20260423070414/en/" rel="nofollow">https://www.businesswire.com/news/home/20260423070414/en/</a></span></p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Investor Contact 
</b><br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:InvestorRelations@neogenomics.com" shape="rect">InvestorRelations@neogenomics.com</a>

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Media Contact 
</b><br xmlns="http://www.w3.org/1999/xhtml"></br>Andrea Sampson
<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:asampson@sampsonprgroup.com" shape="rect">asampson@sampsonprgroup.com</a>

</p>

NeoGenomics Expands Access to Full Oncology Testing Portfolio Through Epic Aura Integration

NeoGenomics Integrates Testing with Epic EHR to Boost Test Adoption

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>EHR-enabled access has the potential to streamline ordering, accelerate clinical decisions, and drive scalable precision oncology adoption


NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>NeoGenomics has integrated its comprehensive oncology testing portfolio with the Epic Aura EHR system. This integration is expected to enhance scalability, driving a potential 20-30% increase in test adoption, and accelerate treatment timelines for cancer patients.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>NeoGenomics integrates testing portfolio with Epic Aura EHR platform.</li><li>Streamlined access may increase test adoption by 20-30% per site.</li><li>Integration supports faster patient treatments and enhances scalability.</li><li>Company&#039;s digital health strategy aims for next-gen diagnostic delivery.</li><li>CEO emphasizes timely diagnostics in routine care settings.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Epic Systems (N/A)</strong>: Integration with Epic enhances NeoGenomics&#039; market reach significantly.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This falls under &#039;Corporate Developments,&#039; highlighting strategic initiatives that enhance service delivery. Such advancements are critical as they drive growth and cement market positioning.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Integration could lead to a significant uptick in revenue from increased test orders.</li><li>Faster treatment timelines may enhance provider relationships and market share.</li><li>Scalability of services poses a competitive edge over other diagnostics companies.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>NeoGenomics&#039;s tests cover solid tumors and hematologic malignancies.</li><li>Integration with Epic EHR supports over 200 hospitals and clinics.</li><li>Expected 20-30% increase in test adoption per site – significant revenue implication.</li><li>CEO Tony Zook highlights potential for improved patient outcomes.</li><li>NeoGenomics is based in Fort Myers, FL, with global operating capabilities.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Invest in NEO expecting short-term gains from increased test adoption following EHR integration.</p>
  </section>
</section>


<p xmlns="http://www.w3.org/1999/xhtml" class="bwalignc">
<i xmlns="http://www.w3.org/1999/xhtml">EHR-enabled access has the potential to streamline ordering, accelerate clinical decisions, and drive scalable precision oncology adoption</i>

</p><p xmlns="http://www.w3.org/1999/xhtml">
<a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.neogenomics.com%2F&amp;esheet=54521005&amp;newsitemid=20260423070414&amp;lan=en-US&amp;anchor=NeoGenomics%2C+Inc.&amp;index=1&amp;md5=624fc482590560018e674c4510e90ddf" shape="rect">NeoGenomics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/NEO">NEO</a>), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that its oncology testing portfolio is now available through <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fshowroom.epic.com%2Fstage%3Fid%3D36&amp;esheet=54521005&amp;newsitemid=20260423070414&amp;lan=en-US&amp;anchor=Epic+Aura&amp;index=2&amp;md5=a48ffc8c690ddc2cf9de757655d23838" shape="rect">Epic Aura</a>, enabling seamless access to oncologists and health systems across the United States through the Epic electronic health record (EHR) workflow.

</p><p xmlns="http://www.w3.org/1999/xhtml">
Through this integration, physicians can order NeoGenomics' comprehensive suite of tests, spanning solid tumors and hematologic malignancies, and view results in the same system they use to manage patient care. This streamlined approach lowers barriers to entry for hospitals and health systems, enhances the scalability of NeoGenomics' testing capabilities, and could drive 20-30% increase<sup xmlns="http://www.w3.org/1999/xhtml">1</sup> in test adoption per site, supporting faster time to treatment for patients facing a cancer diagnosis.

</p><p xmlns="http://www.w3.org/1999/xhtml">
"Clinicians need timely access to the right diagnostics within the systems they already rely on," said Tony Zook, Chief Executive Officer of NeoGenomics. "Successfully integrating with Epic enables us to bring our testing capabilities directly into everyday care delivery, with the potential to help patients begin appropriate therapy sooner while allowing health systems to scale precision oncology more efficiently."

</p><p xmlns="http://www.w3.org/1999/xhtml">
This integration represents a significant step forward in NeoGenomics' digital health strategy, strengthening connectivity across community oncology practices and large health systems. This scalable, "build once, deploy broadly" infrastructure will support the delivery of next-generation diagnostic capabilities, including liquid biopsy and molecular residual disease (MRD).

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">About NeoGenomics</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Forward Looking Statements</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "plan," "can," "could," "would," "may," "will," "believe," "estimate," "forecast," "goal," "project," "guidance," "potential," "intend," "seek," "target" and other words of similar meaning, although not all forward-looking statements include these words. These forward-looking statements include, but are not limited to, statements regarding the expected benefits of the Epic Aura integration, including the potential to streamline test ordering, accelerate clinical decisions, drive adoption of precision oncology, increase test adoption per site and support faster time to treatment, as well as the Company&#39;s Digital Health strategy and the anticipated delivery of next-generation diagnostic capabilities. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Applicable risks and uncertainties include, among others, risks related to the Company's ability to successfully implement and maintain the Epic Aura integration, the willingness of health systems and physicians to adopt the integrated ordering workflow, the Company's ability to achieve projected increases in test adoption, the timing and success of the Company's Digital Health strategy, general market conditions, competitive dynamics and the risks identified under the heading &#34;Risk Factors&#34; contained in the Company&#39;s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the Company&#39;s other filings with the Securities and Exchange Commission.

</p><p xmlns="http://www.w3.org/1999/xhtml">
We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=54521005&amp;newsitemid=20260423070414&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=3&amp;md5=4057d3cf27d552d824b8984c63a9c533" shape="rect">www.sec.gov</a> and in the "Investors" section of our website at ir.neogenomics.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements, whether as a result of new information, future events or otherwise, except as required by law. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Reference</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
1. Huelsman K, Vasiliadis L, Liette A, Wernke K, Parchman A, Maher J, Rice C. Integrating discrete genomic data with an EHR improves patient care, provider satisfaction, and program metrics. <i xmlns="http://www.w3.org/1999/xhtml">Association of Cancer Care Centers</i>. 2024;39(2):12-24. Accessed April 21, 2026. <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fcdn.sanity.io%2Ffiles%2F0vv8moc6%2Faccc-cancer%2Fb351ee63a2f4679660f6e409dd3564c61d15e212.pdf&amp;esheet=54521005&amp;newsitemid=20260423070414&amp;lan=en-US&amp;anchor=https%3A%2F%2Fcdn.sanity.io%2Ffiles%2F0vv8moc6%2Faccc-cancer%2Fb351ee63a2f4679660f6e409dd3564c61d15e212.pdf&amp;index=4&amp;md5=257df8c8c12ed14cf6de7dffd82122c0" shape="rect">https://cdn.sanity.io/files/0vv8moc6/accc-cancer/b351ee63a2f4679660f6e409dd3564c61d15e212.pdf</a>

</p><p xmlns="http://www.w3.org/1999/xhtml"><img xmlns="http://www.w3.org/1999/xhtml" alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260423070414r1&amp;sid=benz2&amp;distro=nx&amp;lang=en" style="width:0;height:0"></img><span xmlns="http://www.w3.org/1999/xhtml" class="bwct31415"></span></p><p xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink"><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-phrase">View source version on businesswire.com: </span><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-link"><a xmlns="http://www.w3.org/1999/xhtml" href="https://www.businesswire.com/news/home/20260423070414/en/" rel="nofollow">https://www.businesswire.com/news/home/20260423070414/en/</a></span></p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Investor Contact 
</b><br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:InvestorRelations@neogenomics.com" shape="rect">InvestorRelations@neogenomics.com</a>

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Media Contact 
</b><br xmlns="http://www.w3.org/1999/xhtml"></br>Andrea Sampson
<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:asampson@sampsonprgroup.com" shape="rect">asampson@sampsonprgroup.com</a>

</p>

NeoGenomics has integrated its comprehensive oncology testing portfolio with the Epic Aura EHR system. This integration is expected to enhance scalability, driving a potential 20-30% increase in test adoption, and accelerate treatment timelines for cancer patients.

NeoGenomics Expands Access to Full Oncology Testing Portfolio Through Epic Aura Integration

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News